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Vaccines that elicit CD8
؉ T-cell responses are routinely tested for immunogenicity in nonhuman primates before advancement to clinical trials. Unfortunately, the magnitude and specificity of vaccine-elicited T-cell responses are variable in currently utilized nonhuman primate populations, owing to heterogeneity in major histocompatibility (MHC) class I genetics. We recently showed that Mauritian cynomolgus macaques (MCM) have unusually simple MHC genetics, with three common haplotypes encoding a shared pair of MHC class IA alleles, Mafa-A*25 and Mafa-A*29. Based on haplotype frequency, we hypothesized that CD8
؉ T-cell responses restricted by these MHC class I alleles would be detected in nearly all MCM. We examine here the frequency and functionality of these two alleles, showing that 88% of MCM express Mafa-A*25 and Mafa-A*29 and that animals carrying these alleles mount three newly defined simian immunodeficiency virus-specific CD8 ؉ T-cell responses. The epitopes recognized by each of these responses accumulated substitutions consistent with immunologic escape, suggesting these responses exert antiviral selective pressure. The demonstration that
Mafa-A*25 and Mafa-A*29 restrict CD8
؉ T-cell responses that are shared among nearly all MCM indicates that these animals are an advantageous nonhuman primate model for comparing the immunogenicity of vaccines that elicit CD8 ؉ T-cell responses.
The immunogenicity and efficacy of vaccines intended for human use are commonly evaluated in rhesus and cynomolgus macaques. Indeed, researchers studied an estimated one million macaques in the search for a polio vaccine (5) . More recently, these animals have become the dominant preclinical model for human immunodeficiency virus (HIV) vaccine evaluation. Rhesus and cynomolgus macaques are susceptible to infection with pathogenic strains of simian immunodeficiency virus (SIV), lentiviruses that share close genetic homology to HIV and cause AIDS-defining illnesses (11, 14) . Vaccines designed to provide sterilizing immunity or control immunodeficiency virus replication can therefore be evaluated in macaques. In addition, the immune systems of humans and macaques are highly similar, providing hope that promising vaccines in macaques can be readily adapted for use in humans. CD8 ϩ T cells are particularly attractive candidates for vaccine development. Several lines of evidence indicate that CD8 ϩ T cells are important to the control of HIV/SIV viral replication. Expansion of HIV/SIV-specific CD8 ϩ T cells during acute viremia is associated with a sharp decline in viral load (6, 21, 50) , while the depletion of CD8 ϩ cells in SIV-infected macaques results in increased viral loads (13, 27) and abrogates the protection elicited by live, attenuated vaccination (30, 38) . Furthermore, major histocompatibility complex (MHC) genotyping studies have identified multiple MHC class I alleles enriched in human and macaque elite controllers (17, 19, 26, 31, 49) .
Recently, Merck and the HIV Vaccine Trials Network cancelled a phase IIb clinical trial evaluating an HIV vaccine designed to elicit CD8 ϩ T-cell immunity. An interim analysis revealed the vaccine was ineffective and that participants with prior immunity to the vaccine vector actually had a higher incidence of HIV infection (7, 28, 39, 43) . Dozens of additional vaccines that aim to elicit CD8 ϩ T cells are in various stages of preclinical and early-stage clinical development, and testing these vaccines in macaques will provide the proof-of-concept necessary to predict their success.
Unfortunately, it has been impossible to definitively associate the breadth, magnitude, or phenotype of SIV-specific CD8 ϩ T-cell responses, elicited by competing vaccine modalities, to viral control. Indian rhesus macaques are the most commonly used model for HIV vaccine testing but have extremely diverse MHC class I genetics, giving rise to heterogeneous CD8 ϩ T-cell responses. SIV derived CD8 ϩ T-cell epitopes have been defined for eight Indian rhesus macaque MHC class I alleles (24) . However, more than 400 classical MHC class I alleles have been identified in rhesus macaques, leaving an enormous gap in our understanding of the overall CD8 ϩ T-cell repertoire following SIV infection (37) . Identifying large cohorts of Indian rhesus macaques matched for one or more MHC class I alleles, and thus predicted to mount CD8 ϩ T-cell responses against the same epitopes, is both difficult and expensive. An abundant nonhuman primate model with limited MHC diversity could standardize testing of each new vaccine entering preclinical development. Indeed, headto-head testing of CD8 ϩ T-cell vaccines is essential to maximize the efficiency of the global vaccine enterprise and prioritize rapid advancement of promising candidates.
In contrast to Indian rhesus macaques, Mauritian cynomolgus macaques (MCM) are an insular population that expanded from a small number of founder animals (23) over the last 500 years. The unique natural history of these animals is manifest by exceptionally low genetic diversity. We have characterized the MHC genetics of this population and found only seven common haplotypes containing fewer than 30 MHC class I alleles (12, 48) . The three most common MHC haplotypes each express Mafa-A*25 and Mafa-A*29. We examine here the frequency and functionality of these two alleles, showing that 88% of MCM express Mafa-A*25 and Mafa-A*29 and that animals carrying these alleles mount three newly defined SIVspecific CD8
ϩ T-cell responses that drive SIV variation. These results suggest that MCM will provide an exceptionally valuable resource for head-to-head evaluations of competing vaccine modalities.
MATERIALS AND METHODS

Animals and infections.
We used nine MCM (cy0114, cy0116, cy0150, cy0161, cy0162, cy0163, cy0164, cy0165, and cy0166) in the present study. All animals were infected with the molecularly cloned SIVmac239 Nef open virus (20) . The Wisconsin National Primate Research Center (University of Wisconsin, Madison, WI) maintained SIV-infected MCM in accordance with experimental protocols approved by the University of Wisconsin Research Animal Resources Center review committee.
Microsatellite analysis of MCM. MCM were haplotyped using our previously described panel of microsatellite markers spanning the MHC region (48) . MCM DNA was isolated from two breeding colonies (Alpha Genesis, Inc., Yemassee, SC, and the National Institute for Biological Standards and Control, Hertfordshire, England [29] ) and from four research cohorts (Massachusetts General Hospital/Harvard Medical School; the University of Miami School of Medicine; the National Cancer Institute, National Institutes of Health [12] ; and the Instituto Superiore di Sanita, National AIDS Center, Rome, Italy), as well as from feral animals from Charles River Laboratories.
Nomenclature for MHC class I alleles. The Mafa-A*25 and Mafa-A*29 class I sequences described in this report are shared by the three most common MCM MHC haplotypes. However, Mafa-A*25 is derived from two distinct MHC class I sequences (Mafa-A*250201 and Mafa-A*250301). These sequences differ by only one conservative isoleucine to methionine substitution in the signal peptide that is cleaved from the mature MHC class I protein. Very recently, the official nomenclature of macaque MHC class I sequences has been updated such that Mafa-A*250201, Mafa-A*250301, and Mafa-A*290101 are now designated Mafa-A1*06302, Mafa-A1*06301, and Mafa-A4*0101, respectively.
Determination of MHC class I peptide binding motifs. We engineered constructs encoding soluble Mafa-A*25 and Mafa-A*29 (sMafa) by deleting the transmembrane and cytoplasmic domains of the ␣-chain in the cDNA. We included a 30-bp tail encoding rat very-low-density-lipoprotein receptor (VLDLr), SVVSTDDDLA, for subsequent purification purposes (18) . These constructs (sMafa-VLDLr) were cloned into the mammalian expression vector pcDNA3.1(Ϫ)/Geneticin (Invitrogen, Carlsbad, CA) and sequenced to ensure the fidelity of each clone. We electroporated these constructs into the HLA class I deficient human B-cell line 721.221 as previously described (41) . Transfectants were cultured in an AcuSyst-Maximizer hollow-fiber bioreactor unit (Biovest International, Minneapolis, MN) in RPMI 1640, 10% fetal calf serum (FCS), and 1% penicillin-streptomycin and were monitored for glucose and oxygen consumption. Approximately 25 mg of each sMafa-VLDLr was collected, clarified by centrifugation (10 min at 3,000 rpm), and stored at 4°C. The clarified supernatants were affinity purified over Sepharose Fast Flow 4B matrix (AmershamPharmacia Biotech, Piscataway, NJ) coupled to VLDLr antibody. We washed the bound sMafa complexes with 20 mM sodium phosphate buffer (pH 7.2) and then eluted with 0.2 M acetic acid (pH 2.7). The eluant was brought to a final concentration of 10% acetic acid and heated to boiling for 10 min. Peptides were purified by passage through a stirred cell ultrafiltration device equipped with a 3-kDa cutoff membrane (Millipore Corp., Bedford, MA) before loading onto a Jupiter Proteo 4 micron C 18 reversed-phase high-pressure liquid chromatography column (Phenomenex, Torrance, CA). We subjected 10% of the eluted peptides to 14 cycles of Edman degradation analysis to produce an endogenous peptide motif. Residues were classified as dominant if they exhibited a 3.5-fold or greater increase in picomoles over the previous round of sequencing, strong if they exhibited a 2.5-to 3.5-fold increase, and weak if they possessed a 2.0-to 2.5-fold increase. Mass spectral analysis was performed via nanoESI on a Q-STAR quadrupole mass spectrometer with a TOF detector and nanoESI ionization source (PerSceptive SCIEX, Foster City, CA). We obtained ion maps in the positive ion mode for several fractions (350 to 2,000 atomic mass units). Ions were manually selected for tandem mass spectrometry analyses sequences verified by submission to Mascot.
Peptides. Peptides used in the present study were synthesized by the Genscript Corp. (Piscataway, NJ) or at the Biotechnology Center at the University of Wisconsin (Madison, WI) using standard tertiary butyloxycarbonyl or fluorenylmethoxycarbonyl solid-phase methods. The NIH AIDS Research and Reference Reagent Program provided all of the 15-mer peptides used to stimulate CD8 ϩ T-cell cultures and determine their restriction (Germantown, MD). Peptide sequences were derived from the SIVmac239 sequence, GenBank accession M33262.
Generation of peptide-specific CD8 ؉ T-cell lines. A total of 5 ϫ 10 6 freshly isolated peripheral blood mononuclear cells (PBMC) were pulsed with 5 M peptide for 90 to 180 min. Cells were washed twice and resuspended in 2 ml of RPMI 1640 (HyClone, Logan, UT) supplemented with L-glutamine (HyClone), antibiotic-antimycotic (HyClone), 100 IU of interleukin-2 (NIH AIDS Reagent Program, Germantown, MD)/ml, and 15% fetal calf serum (HyClone) (R15-100). Seven days later, freshly isolated autologous PBMC were peptide pulsed (5 M) for 90 to 180 min and washed twice. These cells were then mixed at a ratio of 1:1 with the CD8 ϩ T-cell culture and resuspended at up to 5 ϫ 10 6 total cells per 5 ml of R15-100. Thereafter, CD8
ϩ T-cell lines were stimulated by this method once every 1 to 2 weeks with peptide-pulsed and gamma-irradiated autologous PBMC (4,000 rads) or MHC-matched B-lymphoblastoid cell lines (9,000 rads).
Generation of membrane bound MHC class I transferents. Transferents expressing single MCM MHC class I alleles were created using HLA-deficient human B-lymphoblastoid cell line 721.221 as previously described (40) . Briefly, full-length MHC class I amplicons were ligated into pcDNA3.1(ϩ) (Invitrogen, Carlsbad, CA) between the NotI and KpnI restriction sites. These constructs were then transfected into 721.221 cells by using the Nucleofector kit C (Amaxa, Gaithersburg, MD). After 3 weeks in R10 culture, 721.221 cells were surface stained with an anti-MHC class I antibody (W6/32-PE, provided courtesy of David Watkins), and those expressing MHC class I were magnetically isolated by using anti-phycoerythrin (PE) microbeads with LS columns (Miltenyi, Auburn, CA). After MHC class I selection, transferents were maintained in R10 under G418 (Mediatech, Manassas, VA) drug selection.
Intracellular cytokine staining. Activation of CD8 ϩ T-cell lines was measured by gamma interferon (IFN-␥) and tumor necrosis factor alpha (TNF-␣) intracellular cytokine staining as previously described (25, 47) . Briefly, 10 5 antigenpresenting cells (B-lymphoblastoid cell lines or MHC class I transferents) were peptide pulsed and cocultured with 2 ϫ 10 5 CD8 ϩ T cells. Cells were surface stained with CD8-Pacific Blue (BD Biosciences, Franklin Lakes, NJ) and CD3-Alexa Fluor 700 (BD Biosciences), washed twice in 1ϫ phosphate-buffered saline (HyClone) supplemented with 10% fetal calf serum (HyClone) (fluorescenceactivated cell sorting buffer), fixed with 2% paraformaldehyde (Fisher Scientific, Itasca, IL), and left at 4°C overnight. Cells were permeabilized in fluorescenceactivated cell sorting buffer containing 0.1% saponin (saponin buffer) and stained with IFN-␥-fluorescein isothiocyanate (FITC) (BD Biosciences) and TNF-␣-PE (BD Biosciences), washed three times in saponin buffer, and fixed with 2% paraformaldehyde. Flow cytometry was conducted on a BD-LSRII and analysis was performed by using FlowJo software version 8.8.2 (TreeStar, Ashland, OR).
IFN-␥ ELISPOT assays. PBMC were isolated from EDTA anticoagulated whole blood by using Ficoll-Paque Plus (GE Healthcare Bioscience, Uppsala, Sweden) and density centrifugation. Precoated monkey IFN-␥ ELISpot PLUS plates were purchased from Mabtech, Inc. (Mariemont, OH), and experiments were conducted according to manufacturer's recommendations. Each well contained 10 5 cells in 100 l of R10. Cells were incubated with 10 M peptide. Wells were imaged with an AID enzyme-linked immunospot (ELISPOT) reader, and spots were counted by an automated system with set parameters for size, intensity, and gradient. Responses were considered positive if the mean number of spot-forming cells (SFC) of triplicate sample wells exceed background plus two standard deviations. Responses of less than 50 SFC per million PBMC were considered negative (below the limit of detection).
Viral sequencing. Cell-free plasma was obtained from EDTA anticoagulated whole blood by using Ficoll-Paque Plus (GE Healthcare Bioscience) and density centrifugation. Viral RNA in the plasma was isolated by using the QIAamp MinElute virus spin kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. Viral RNA was reverse transcribed and amplified by using the One-Step reverse transcription-PCR kit (Qiagen), generating amplicons spanning the epitopes of interest from the SIVmac239 open reading frame. The reverse transcription-PCR conditions were as follows: 50°C for 30 min; 95°C for 15 min; 45 cycles of 98°C for 1 min, 58°C for 1 min, and 72°C for 2.5 min; and 68°C for 20 min. The primer sets used were: 2205-F (5Ј-CAGGTTCTACAAA AGTTTAAGAGC-3Ј) and 2900-R (5Ј-ATCATCAGCCCCTGTATC-3Ј); 3790-F (5Ј-AATGGATGGGGTACGAATTG-3Ј) and 4563-R (5Ј-TCAATGCC ATGAGAAATGC-3Ј); and 9493-F (5Ј-CTTGTGAGGGACAGAAATACAAT C-3Ј) and 10235-R (5Ј-GAATACAGAGCGAAATGCAGTG-3Ј). Amplicons were sequenced on an ABI 3730xl DNA analyzer using ET terminator technology (GE Healthcare). Sequencing primers included those mentioned above, as well as several nested primers: 2507-F (5Ј-GACACTCTGCAAGGCAATGC-3Ј) and 2712-R (5Ј-ATCCACAGCTGGGTCCTCTG-3Ј); 3984-F (5Ј-GTTCAGTG GACTGAGATGGC-3Ј) and 4312-R (5Ј-GTCCACCACTGTTCCCATAC-3Ј); and 9664-F (5Ј-TGAGTTACAAATTGGCAATAGACAT-3Ј) and 10146-R (5Ј-CTTGTGGAAAGTCCCTGC-3Ј). Sequences were compared to the reference sequence of the molecularly cloned SIVmac239 (GenBank accession M33262) using CodonCode Aligner (CodonCode Corp., Dedham, MA).
RESULTS
Most MCM possess at least one copy of a haplotype expressing Mafa-A*25 and Mafa-A*29. The natural history of MCM indicates that this exotic, invasive population arose from a few individuals within the last 500 years. We have previously published microsatellite analyses from 141 feral MCM and defined seven common MHC haplotypes (12, 48) . We cloned and sequenced MHC alleles from a representative group of these animals and found a pair of MHC class IA alleles shared between the three most common haplotypes. To further investigate MHC haplotype frequency, we expanded our microsatellite analyses to more than one thousand MCM (1,033 total MCM, Table 1 ). These animals represent two breeding colonies, four research cohorts, and feral animals imported by Charles River. Consistent with previous work, we found that 88% of these animals carried at least one of the three common haplotypes expressing Mafa-A*25 and Mafa-A*29.
The high frequency of ϩ T-cell epitopes from any pathogen, irrespective of a priori knowledge of immune responses. The high frequency of Mafa-A*25 and -A*29 makes these alleles particularly important to studies addressing infectious diseases in MCM, provided they are shown to be functional elements of an adaptive immune response. We investigated the functionality of these alleles by isolating Mafa-A*25 or -A*29 translational products from MHC class I transferents. We isolated the endogenous peptides bound to these MHC proteins and sequenced them by Edman degradation. The compilation of these sequences was used to generate peptide binding motifs for each allele (Table 2 ). These peptide binding motifs can be used to help predict CD8 ϩ T-cell responses in nearly 9 out of 10 cynomolgus macaques from the island of Mauritius.
The Mafa-A*25 and -A*29 peptide binding motifs are strikingly similar, sharing one or more amino acids at positions 1, 2, 3, 4, and 9. Interestingly, the Mafa-A*29 binding motif also shares separate similarities to the previously described Mamu-A*01 binding motif (3, 35, 42) . Both binding motifs have a threonine at position two, a proline at position three, and a phenylalanine or leucine at position nine. In support of this, we have identified a Mamu-A*01-restricted CD8 ϩ T-cell epitope (Pol 588-596 QVPKFHLPV) (2) that is bound and presented to MCM CD8
ϩ T cells by Mafa-A*29. Identification of three novel SIV-specific CD8 T-cell responses in MCM. We identified prospective Mafa-A*25 and -A*29 CD8
ϩ T-cell epitopes by scanning the SIV proteome for variation in chronically infected MCM (data not shown) and comparing these regions of variation to our established peptide binding motifs. Based on our results, we initiated polyclonal CD8 ϩ T-cell lines from three SIVmac239-infected MCM (cy0114, cy0116, and cy0150) by stimulation with 15-mers (overlapping by 11 amino acids) corresponding to Nef 97-115, Pol 589-603, and Gag 381-399. To define the MHC restriction of these responses, we constructed 721.221 transferents expressing either Mafa-A*25, -A*29, or -B*44 (40) . The SIVmac239 15-mer peptides used to stimulate our CD8 ϩ T cells did not contain sequences predicted to bind Mafa-B*44, and this transferent was included as a negative control. We pulsed each transferent separately with our sets of 15-mer peptides. CD8 ϩ T cells were then added, and activation was measured by intracellular staining of IFN-␥ and TNF-␣ (Fig.  1) . CD8 ϩ T cells specific against Gag 381-399 and Nef 97-115 were activated by transferents expressing Mafa-A*25, while those specific against Pol 589-603 were activated by transfer- We then defined the optimal epitopes bound by Mafa-A*25 and -A*29. We pulsed transferents expressing Mafa-A*25 (Gag and Nef responses) or Mafa-A*29 (Pol response) with panels of overlapping 8-, 9-, 10-, and 11-mer peptides (see Fig. S1 in the supplemental material). We then added CD8 ϩ T cells, and activation was measured by intracellular staining of IFN-␥ and TNF-␣ (data not shown). Peptides eliciting robust responses were selected from these panels for further analysis. We pulsed transferents with serial dilutions of these peptides, with final concentrations ranging from 1 M to 1 nM. We then added CD8 ϩ T cells and activation was measured by intracellular staining of IFN-␥ and TNF-␣ (Fig. 2) . Optimal responses were elicited by Gag GW9 (GPRKPIKCW; 50% effective concentration [EC 50 ] ϭ 7.48 nM), Nef RM9 (RPKVPLRTM; EC 50 ϭ 33.67 nM), and Pol QP8 (QVPKFHLP; EC 50 ϭ 15.70 nM).
Based on our peptide binding motifs, each of these epitopes contains one or more amino acids that bind dominantly to predicted MHC class I peptide anchors (position 2 or 9) (34) ( Table 2 ). In addition, we have successfully generated functional MHC class I tetramers for all three of these responses using these optimal epitopes (data not shown).
Ex vivo detection of Mafa-A*25-and Mafa-A*29-restricted CD8
؉ T-cell responses by IFN-␥ ELISPOT. We next assessed the consistency of our newly discovered responses by measuring them ex vivo in six SIVmac239-infected MCM (cy0161 to cy0166) expressing Mafa-A*25 and -A*29. We followed the responses longitudinally by IFN-␥ ELISPOT across the first 6 months of infection with time points at weeks 4, 14, and 24. We considered responses positive if their mean was greater than two standard deviations above the negative mean, with a minimum cutoff of 50 SFC per one million PBMC.
The magnitude and timing of the three responses varied greatly between the animals (Fig. 3) . cy0162 was the only animal that responded to all three peptides at 4 weeks postinfection (wpi), and all three of these responses expanded through 14 wpi. cy0166 had the largest responses to the Gag and Nef peptides at 4 wpi, but a response to the Pol peptide was not seen until 14 wpi. cy0163, cy0164, and cy0165 all exhibited at least one positive low-level response against each of the three peptides by 14 wpi. In contrast, cy0161 mounted only one positive low-level response to the Nef peptide at 4 wpi.
We initially hypothesized that all six MCM expressing Mafa-A*25 and -A*29 would mount similar responses against each of the three epitopes. Instead, the emerging response patterns varied greatly, both in magnitude and timing. It is difficult to make overarching predictions on the consistency of these re- Mafa-A*25
a Amino acid residues shared between the Mafa-A*29 and Mamu-A*01 binding motifs are indicated by an asterisk. Italicized amino acid residues were determined by individual ligand sequences. Based on Edman degradation, residues were classified as dominant if they exhibited a Ն3.5-fold increase in picomoles over the previous round of sequencing, strong if they exhibited a 2.5-to 3.5-fold increase, and weak if they exhibited a 2.0-to 2.5-fold increase.
sponses within the MCM population given the small size of our data set. However, five of six MCM did mount positive responses to each of the peptides at one or more time points.
Viral sequencing reveals functionality of shared responses. We next sought to determine whether the variable kinetics of our CD8 ϩ T-cell responses could be attributed to viral mutations. We sequenced regions of the viral genome encoding each of the three CD8 T-cell epitopes at multiple time points during the first 5 months of infection. We discovered that viral mutations accrued within each of these epitopes during the first few months (Fig. 4 and see Fig. S2 in the supplemental material). The Gag and Nef epitopes both accumulated mutations with rapid kinetics in all of the animals. Five of six animals showed variation in the Gag epitope by 6 wpi. All six animals showed variation within the Nef epitope by 6 wpi. The kinetics of mutation was slower for the Pol epitope, with the earliest variation seen by 8 wpi in two of six animals. Importantly, with the exception of the Pol epitope in cy0166, all six animals showed variation in each of the SIVmac239 epitopes within the first 20 weeks, implying that these highly common responses are exerting antiviral pressure in MCM expressing Mafa-A*25 and -A*29. Furthermore, the lack of variation within the Pol epitope in cy0166 may explain why this animal maintained the strongest response against the Pol peptide through 24 wpi (Fig. 3) .
Remarkably, one animal harbored mutations within the Nef epitope as early as 2 wpi. This represents the most rapid CD8 ϩ T-cell selection documented in nonimmunized, SIVmac239-infected macaques. Interestingly, this early variation was seen in cy0161, whose only measurable IFN-␥ ELISPOT response was against the Nef peptide at 4 wpi.
DISCUSSION
Mauritian cynomolgus macaques are susceptible to SIV/ SHIV infection and progress to AIDS, making them a viable
FIG. 2. Determination of optimal CD8
ϩ T-cell epitopes. 721.221 transferents expressing the appropriate restricting MHC class I allele were pulsed with serial dilutions of prospective optimal peptides. SIV-specific CD8 ϩ T-cell lines were added, and activation was measured by intracellular staining of IFN␥-FITC and TNF-␣-PE. CD8 ϩ T-cell responses are displayed in terms of the percent maximum response. The actual percentage of CD3 ϩ CD8 ϩ cells responding to 10 3 nM of peptide is listed beneath each peptide. Each condition was performed in triplicate, and optimal epitopes were confirmed in at least two separate experiments.
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model to study HIV pathogenesis (12, 36, 48) . There are many similarities between SIV-infected cynomolgus and rhesus macaques. Viral replication occurs with similar kinetics after infection, although set point viral loads tend to be lower in cynomolgus macaques (36, 44) . SIV-specific CD8 ϩ T-cell responses expand during the first few weeks of infection and are temporally associated with the resolution of peak viremia. Pronounced CD4
ϩ T-cell loss in the periphery occurs within the first few weeks of infection, although cynomolgus macaques trend toward lower levels of lymphopenia (36) . Vaccination with live, attenuated SIV lowers acute and chronic phase viral loads in rhesus macaques challenged with pathogenic strains of SIV, and similar protection has been documented in MCM (4). Finally, certain MHC class I and II alleles appear protective in SIV-infected rhesus macaques (15, 26, 31, 49) , and similar associations between MCM MHC haplotypes and viral control have been recently reported (12) .
The extraordinary frequency of Mafa-A*25 and -A*29 within the MCM population is somewhat perplexing given the relatively low frequency of these alleles among non-MCM. Although it is entirely plausible that the small founder population of MCM predominantly carried haplotypes expressing Mafa-A*25 and -A*29, it is also possible that Mafa-A*25 and -A*29 were naturally selected within the MCM population by a pathogen endogenous to Mauritius. Malaria spread across Mauritius in the mid-19th century, killing nearly 15% of the human population (16) . MCM are susceptible to at least seven different species of Plasmodium (10), and it is possible that they experienced a similar epidemic that naturally selected for certain MHC alleles. Indeed, HLA-B*53 restricts malaria-spe- 
cific CD8
ϩ T-cell responses and has been associated with protection against severe malaria in West Africans infected with Plasmodium falciparum (1) . Mafa-A*25 or -A*29 may also have restricted CD8
ϩ T-cell responses that protected MCM parasite carriers from disease progression and death. These alleles are tightly linked and consistently cosegregate. Therefore, if either allele was protective, it would explain the high frequency of both alleles within the MCM population.
Due to the novelty of the MCM model, little is known about the CD8 ϩ T-cell responses mounted after SIV infection. Only one MCM SIV-specific CD8 ϩ T-cell response has been previously identified and published, and the restriction of this response was not determined (32) . Here we describe the first SIV-specific CD8 ϩ T-cell responses restricted by Mafa-A*25 and -A*29. These responses were initially identified by using an unconventional viral sequencing method. We scanned for acute-and chronic-phase viral variation among animals sharing only Mafa-A*25 and -A*29, and regions with shared variation were flagged as potential CD8 ϩ T-cell epitopes. Cell lines were then derived using 15-mers spanning these regions of interest. This technique facilitates rapid identification of potential CD8
ϩ T-cell epitopes, especially those escaping during the acute phase of infection. However, it is important to note that this technique is unable to identify CD8 ϩ T-cell responses that do not induce viral variation. We are currently using a more conventional method of testing overlapping peptides spanning the SIV genome to discover additional responses restricted by Mafa-A*25 and -A*29.
Knowledge of which antigens are predicted to bind MHC class I molecules significantly accelerates identification of novel CD8 ϩ T-cell responses. To this end, our group has characterized the peptide binding motifs of these two unprecedentedly common MHC class I alleles. These peptide binding motifs can not only be used to identify novel SIV epitopes but also harnessed to identify responses against other high-profile pathogens such as influenza, malaria, or tuberculosis. The expeditious identification of CD8 ϩ T-cell epitopes bound by high-frequency MHC class I molecules, such as Mafa-A*25 and -A*29, will allow the MCM model to be rapidly integrated into other areas of infectious disease research and vaccine development.
The identification of SIV-specific CD8 ϩ T-cell responses in MCM increases their value as an abundant and advantageous nonhuman primate model for the testing of HIV vaccines designed to elicit CD8 ϩ T-cell responses. The MCM population has expanded to more than 50,000 animals, 88% of which are predicted to express the MHC class I alleles Mafa-A*25 and -A*29. SIV-specific CD8 ϩ T-cell responses have been identified for only a few restricting MHC class I alleles in rhesus macaques. Due to this constraint, SIV vaccines designed to elicit CD8 ϩ T-cell responses must be tested in animals carrying one or more of these alleles, making these animals a scarce commodity. Rhesus macaque breeding colonies artificially select for these heavily studied MHC class I alleles, but the high demand for these animals has made it difficult to collect large groups of MHC class I-matched animals for SIV vaccine studies. Furthermore, the MHC class I alleles that are matched in one vaccine study may not be the same as those matched in other studies examining different vaccine approaches. There are currently dozens of HIV vaccines in preclinical stages of development, and MCM provide the means to test each of these vaccines in animals sharing the same two MHC class I alleles. Furthermore, the MCM model is not limited to the testing of vaccines currently in development but rather could also be used to retrospectively test failed vaccines, such as Merck's STEP vaccine. These studies may provide basic, fundamental insight into the weaknesses of these vaccines. The commonality of Mafa-A*25 and -A*29 within the MCM population makes this model an important new tool for disease research. However, this population trait also has two specific drawbacks. First, the limited MHC diversity of the MCM model stands in stark contrast to the MHC heterogeneity found in humans. Prophylactic HIV vaccines intended for worldwide use must protect recipients with diverse MHC genetics, and while MCM can provide standardized testing of the immunogenicity and efficacy of large numbers of vaccine modalities, it has yet to be shown that these results are applicable to rhesus macaque or human populations. Second, generating large cohorts of SIV-infected MCM expressing neither Mafa-A*25 nor Mafa-A*29 becomes challenging. Certain rhesus macaque MHC class I alleles have been correlated to elite control of SIV, but large cohorts of genetically diverse SIV-infected animals were required for these analyses. To date, we have infected only 14 MCM with SIVmac239, and all of these animals express Mafa-A*25 and -A*29. Therefore, we cannot currently associate these alleles, or the responses they restrict, to a particular SIVmac239 infection outcome. In addition, we cannot conclude with certainty that the viral mutations we have described are a direct consequence of CD8 ϩ T-cell pressure. However, bulk viral sequencing from all three epitopes shows variation at a typical MHC class I anchor (position 2) (34), implying that these mutations allow the virus to evade CD8 ϩ T-cell responses.
MCM are an appealing alternative to the rhesus macaque model, but they also have limitations. First, set point viral loads are generally lower in SIVmac-infected cynomolgus macaques compared to rhesus macaques (36, 44) . However, serial passage of SIVmac viruses through cynomolgus macaques could generate a more pathogenic strain (9) , recapitulating the key features of SIVmac infection in rhesus macaques. Second, very few SIV-specific CD8 ϩ T-cell responses have been identified in MCM, making complex studies of SIV pathogenesis and corresponding immune responses difficult to interpret. The identification of additional SIV-derived CD8 ϩ T-cell epitopes is therefore necessary to advance this model. Third, viral evolution has been monitored in only a small number of MCM infected with SIV, and more infected animals are necessary to determine associations between viral variation, viral fitness, and disease outcome. Finally, MCM are generally smaller than rhesus macaques, limiting the volume of blood accessible to researchers. This places constraints on the number of cells and the volume of plasma available for ex vivo or in vitro assays.
Despite these current shortcomings, MCM are an extremely promising novel model for studies comparing SIV vaccine approaches. Large numbers of MCM sharing two MHC class I alleles are available for head-to-head vaccine testing. MCM are susceptible to infection with SIV/SHIV and SIV-specific CD8 ϩ T-cell responses restricted by Mafa-A*25 and -A*29 appear to exert antiviral pressure, leading to viral variation as early as 2 weeks postinfection. Further identification of SIVspecific CD8
ϩ T-cell responses in MCM will enhance the power of the model and allow researchers to comprehensively test different SIV vaccine approaches, accelerating preclinical vaccine development.
